Outlook Therapeutics Scores Breakthrough with FDA Approval of LYTENAVA

Outlook Therapeutics has secured FDA approval for its LYTENAVA, a bevacizumab formulation designed specifically for intravitreal administration in wet age-related macular degeneration (AMD) patients.

The new treatment is the first ophthalmic bevacizumab to receive FDA clearance and marks a significant milestone for Outlook Therapeutics. The company believes LYTENAVA will become the standard for bevacizumab therapy in this patient population, given its approval and the fact that bevacizumab already accounts for most first-line anti-VEGF treatment in wet AMD.

According to CEO Bob Jahr, physicians previously relied on repackaged formulations intended for intravenous use. This lack of a purpose-built ophthalmic formulation has been a long-standing issue in the retina community, as noted by Firas M. Rahhal, MD, Chairman of Ophthalmology at Good Samaritan Hospital in Los Angeles.

LYTENAVA enters the U.S. anti-VEGF retina market, which is estimated to be worth around $8.5 billion annually. The company plans to make LYTENAVA available to eligible patients before year-end and has already commenced commercial launches in Germany, Austria, and the UK.